Calmangafodipir

Phase 3Small molecule

EEgetis Therapeutics

Calmangafodipir is one of 66 small molecule programs targeting Peripheral Neuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral NeuropathyActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Peripheral NeuropathyPhase 3

Active, not recruiting

Metastatic Colorectal CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Innohep

Alnylam Pharmaceuticals

Phase 3

1 2

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

2 3

Xeloda

Roche

Phase 3

3 4

XL092

Roche

Phase 3

1 5

Anlotinib Hydrochloride

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 6

Oxaliplatin, /m2

Roche

Phase 3

1 7

Eylea

Regeneron

Preclinical

18 8

Leucovorin and 5-FU

AAkeso

Phase 3

2 9

Capecitabine, /m2

Roche

Phase 3

1 10

Calmangafodipir

EEgetis Therapeutics

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Peripheral Neuropathy1 trial

Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer

Terminated·EEgetis Therapeutics·Phase 3·NCT04034355·301 enrolled

Metastatic Colorectal Cancer1 trial

Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)

Terminated·EEgetis Therapeutics·Phase 3·NCT03654729·291 enrolled

Unspecified1 trial

SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects

Completed·EEgetis Therapeutics·Phase 1·NCT03430999·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Calmangafodipir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Calmangafodipir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Calmangafodipir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Egetis Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEgetis Therapeutics

Calmangafodipir

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Peripheral Neuropathy1 trial

Metastatic Colorectal Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News